Ophthalmic Antivirals

Key Points

  • Trifluridine is a primary topical antiviral for herpes simplex ocular infections.
  • Systemic absorption is minimal, so most adverse effects are local ocular effects.
  • If there is no improvement after about 7 days, reassessment and alternate therapy should be considered.
  • Continuous use beyond about 21 days should be avoided due to ocular toxicity risk.
  • Storage/handling and biohazard-style disposal teaching are essential safety components.

Class Overview

Ocular antivirals suppress local viral replication in herpes-related keratoconjunctival disease. Topical therapy aims to heal epithelial defects while limiting progression and complications.

Prototype Dosing

DrugTypical Adult Ophthalmic DosingKey Indications
Trifluridine 1%1 drop every 2 hours while awake (max 9 drops/day) until complete re-epithelialization, then 1 drop every 4 hours while awake for 7 more days (minimum 5 drops/day)Primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV types 1 and 2

Adverse Effects and Contraindications

  • Mild transient burning/stinging
  • Palpebral conjunctival edema
  • Hyperemia, epithelial keratopathy, keratitis sicca
  • Increased IOP or ocular-toxicity patterns with prolonged exposure
  • Rare retinal-detachment warning symptoms may occur

Contraindication is primarily hypersensitivity to active/inactive ingredients.

Nursing Assessment and Interventions

  • Assess decline in conjunctival erythema and corneal-healing progression.
  • If no improvement by day 7 or re-epithelialization remains incomplete, escalate for treatment reassessment.
  • Avoid continuous therapy beyond 21 days unless specialist-directed.
  • Screen for retinal-detachment cues (floaters, flashes, curtain-like shadow) and escalate immediately if present.
  • Use contagious-infection precautions in care interactions.

Client Education

  • Store refrigerated (about 36 F to 48 F) and bring solution to room temperature before instillation.
  • Wash hands and exposed skin thoroughly after handling medication.
  • Use proper no-touch instillation and disposal technique for container/drug remnants.
  • Report worsening vision, flashes/floaters, or persistent severe irritation urgently.
  • Do not assume HSV eradication after symptom improvement; recurrence is possible.